Determining factors related to poor quality of life in patients with axial spondyloarthritis : results from the British Society for Rheumatology Biologics Register (BSRBR-AS) by Macfarlane, Gary et al.
  
This article has been accepted for publication in Annals of the Rheumatic Diseases following peer review, and the Version of 
Record can be accessed online at http://dx.doi.org/10.1136/annrheumdis-2019-216143 © Author(s) (or their 
employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ. 
 
Determining factors related to poor quality of life in patients with axial spondyloarthritis: 
results from the British Society for Rheumatology Biologics Register (BSRBR-AS) 
Gary J Macfarlane (1)*^, Ovidiu Rotariu (1)*, Gareth T Jones (1), Ejaz Pathan (2), Linda E Dean 
(1) 
 
 
1. Epidemiology Group and Aberdeen Centre for Arthritis and Musculoskeletal Health (ACAMH), 
School of Medicine, Medical Science and Nutrition, University of Aberdeen, Aberdeen, United 
Kingdom 
2. Spondylitis Program, Department of Rheumatology, Toronto Western Hospital, Toronto, 
Canada. 
 
*These authors have contributed to the work equally 
 
 
 
Corresponding Author 
Gary J Macfarlane 
Chair in Epidemiology and Dean of Research and Knowledge Exchange (Life Sciences and Medicine) 
University of Aberdeen 
School of Medicine, Medical Sciences and Nutrition 
Foresterhill, Aberdeen 
United Kingdom  
AB25 2ZD 
t: +44 (0)1224 437143 
 
tw: @AberdeenEpi 
ORCID ID 0000-0003-2322-3314 
 
 
Word count: 3107 
  
 
  
  
ABSTRACT 
Objective To determine modifiable factors associated with poor quality of life (QoL) in patients with 
axial spondyloarthritis.  
Methods Analysis of data from the British Society for Rheumatology Biologics Register in Ankylosing 
Spondylitis (BSRBR-AS) and validation of a previous model, using data from 1810 patients with axSpA 
recruited 2012-17. Data collected included clinical and patient-reported measures. QoL was assessed 
using the Ankylosing Spondylitis Quality of Life measure (ASQoL). Linear regression models predicting 
ASQoL score were used firstly to validate a previous model from a national study, to extend this with 
additional information available in BSRBR-AS and finally to identify a “de novo” model from BSRBR-AS 
of which factors impact on poor QoL..  
Results Four out of five factors included in a previous model of poor QoL in axSpA patients were 
confirmed: Bath measures of disease activity (BASDAI) and function (BASFI), fatigue and widespread 
pain, although the performance of the model was improved by the addition of measures of mood and 
sleep disturbance. In a “de novo” model in BSRBR-AS there were six  factors (other than disease activity 
and function) which predicted ASQoL:  depression (β=0.16), sleep disturbance (β=0.08), activity 
impairment (β=0.04), fibromyalgia (symptom severity scale (β=0.24) and widespread pain index 
(β=0.10)) and tobacco smoking (β=0.65). 
Conclusion This study confirms that poor QoL in patients with axSpA, in addition to high disease 
activity and poor function, is independently influenced by sleep disturbance, mood and widespread 
pain These additional factors are not considered targets for treatment in current EULAR guidelines for 
managing the condition. 
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INTRODUCTION 
 
When treating people with axial spondyloarthritis (axSpA) and other inflammatory conditions, 
rheumatologists are focussed on reducing disease activity and in so doing aim to reduce the impact 
which the disease has on their lives. The ultimate aim, however, is to improve patients’ quality of life 
(QoL). Reducing disease activity is one way to do that, but there may be other factors not directly 
captured by disease activity measures, which impact on QoL. AxSpA has an impact on people’s working 
lives, mental health and physical health symptoms, such as pain and fatigue, have been shown to have 
an important influence on QoL.[1,2] Further, we (and others) have shown that pharmacological 
therapy targeted at reducing disease activity in inflammatory arthritis may have modest effects on 
aspects such as mental health[3], fatigue[4] and work productivity.[5] 
 
Previously, in an analysis of 959 patients from a national disease register (Scotland Registry for 
Ankylosing Spondylitis (SIRAS)), we have shown that five potentially modifiable factors predict poor 
QoL (using the Ankylosing Spondylitis Quality of Life Scale (ASQoL)[6]): high disease activity, poor 
physical function, fatigue, chronic widespread pain and poor spinal mobility.[7] Of these factors, 
disease activity had the lowest (20%) population attributable risk for poor QoL. In addition, there were 
a number of nonmodifiable factors or at least not easily modifiable in the clinic, which were also 
related to poor quality of life: female sex, fewer years of education, not in full-time employment, living 
in areas with higher deprivation, not able to drive and history of peripheral joint involvement. We 
concluded that “these findings provide evidence that in addition to traditional clinical targets ….. , 
focus on nonspecific symptoms (CWP and fatigue), perhaps with nonpharmacological therapies, may 
yield important improvements in QoL.”. The positive predictive value for poor QoL varied from around 
0% and 15% in those with 1 or two modifiable factors to around 60% and 80% in those with 4 or 5 
such factors respectively.  
 
The aims of the current study, using a Great Britain-wide registry of axial spondyloarthritis (British 
Society for Rheumatology Biologics Register in Ankylosing Spondylitis: BSRBR-AS), is a) to validate the 
previous model (above) of modifiable factors linked to poor QoL, b) given that the BSRBR-AS has 
collected a wider set of variables to determine whether these additional variables (related to mood 
and sleep disturbance) are independent in predicting poor QoL and c) using the BSRBR-AS to develop 
a model predicting poor QoL “de novo”, to determine how consistent are the factors which predict 
poor QoL across both populations 
 
  
METHODS 
 
The BSRBR-AS is a prospective cohort study of people with axSpA. Patients were naïve to biologic 
therapy on recruitment but some were about to start such therapy (the biologic cohort) while others 
continued on other therapy (non-biologic cohort). The study protocol has been published 
previously.[8] Briefly, recruitment took place across 83 secondary care centres between December 
2012 and December 2017, initially for those patients, aged at least 16 years, meeting the Assessment 
of SpondyloArthritis international Society (ASAS) imaging criteria for axSpA[9] or the modified New 
York (mNY) definition of Ankylosing Spondylitis.[10] From November 2014 those meeting the ASAS 
clinical criteria were also eligible. Clinical data were collected from medical notes and patients 
completed questionnaires which were handed out in the clinic and could be completed there, or at 
home and posted back to the recruitment centre. For the current study, the data used was from the 
time of recruitment (for non-biological cohort) and just prior to commencing biological therapy 
(biological cohort) which was also mainly at the time of recruitment. QoL was assessed by ASQoL,[6] 
an 18-item questionnaire which gives a score between 0 (best QoL) and 18 (worst QoL).  
Clinical information included extra-spinal manifestations (uveitis, psoriasis, inflammatory bowel 
disease (IBD), enthesitis, dactylitis), inflammatory markers (C-Reactive Protein (CRP),   peripheral joint 
involvement, symptom duration, body mass index (BMI), and information on 14 comorbidities  
(related to cardiovascular, respiratory, gastrointestinal, renal, neurological conditions and cancer) 
Patient reported measures included age, gender, level of education, employment status and lifestyle 
factors (tobacco smoking and alcohol intake) as well as Bath Ankylosing Spondylitis indices for disease 
activity (BASDAI),[11] function (BASFI),[12] and metrology (BASMI).[13] These Bath indices all produce 
scores ranging from 0 – 10 (least to most severe). Participant postcodes were used to determine a 
deprivation quintile, with reference to either the population of Scotland or England & Wales.[14-16] 
This ranged from 1 (most deprived) to 5 (least deprived). Mental health was assessed by the Hospital 
Anxiety and Depression Scale (HADS) scored from 0 (best) to 21 (worst).[17] Overall work impairment 
(including absenteeism, presenteeism) and other activity (non-work) impairment by the Work 
Productivity and Activity Impairment Specific Health Problem (WPAI:SHP), all scored from 0-
100%.[18,19] The widespread pain index (WPI) (0 – 19) and symptom severity scale (SSS) were 
assessed through the 2011 fibromyalgia “research” criteria.[20] This was only collected amongst 
persons recruited from August 2015. Fatigue was collected through the Chalder fatigue scale (CFS, 0 
– 33),[21] and sleep disturbance by the Jenkins Sleep Evaluation Questionnaire (0 – 20),[22] with 
higher scores on each indicating worse state. 
  
Ethical approval was obtained from the National Research Ethics Service Committee North East—
County Durham and Tees Valley (reference 11/NE/0374) and informed consent was obtained from all 
participants. Patients attended meetings to identify priority areas for analysis. 
 
Analysis 
In validating the model linking modifiable factors to quality of life previously reported by Dean et al,[7] 
the five modifiable factors reported (fatigue, BASFI, Chronic widespread pain (CWP), BASDAI and 
BASMI) were included in a multivariable linear regression model. The model was adjusted for non-
modifiable factors associated with QoL on univariable analysis at p ≤ 0.2. The current study did not 
have information available to determine the presence of CWP according to the American College of 
Rheumatology (ACR) 1990 criteria for fibromyalgia,[23] and instead used the WPI subscale of the 2011 
“research” criteria for fibromyalgia.[20] Building upon this 5 factor model, the second analysis offered 
three additional modifiable factors (anxiety, depression and sleep disturbance), which were available 
in BSRBR-AS, but had not been available within SIRAS. The stepwise selection therefore had eight 
candidate variables. Variables were entered into the model at p ≤ 0.1 and excluded at p ≥ 0.15. 
Adjustment for nonmodifiable factors was applied as previously. The third analysis was a multivariable 
linear regression model, “de novo”, with forward stepwise selection, using modifiable factors from 
BSRBR-AS with p ≤0.2 from the univariable analysis. The model examined which factors, in addition to 
disease activity and function, influenced poor quality of life, but omitted the work productivity factors 
(absenteeism, presenteeism and work impairment), which were only available for employed 
participants. Adjustment for nonmodifiable factors was applied as previously. For each model, once 
the variables to be included were determined, the model was re-run using all the participants with 
data for the included variables (rather than only participants with data available for each of the 
candidate variables). 
 
All statistical analysis was undertaken using STATA (StataCorp LP version 15) and on the August 2017 
version of the BSRBR-AS dataset. 
  
  
RESULTS 
 
A total of 1810 participants were eligible for the current analyses. Approximately two-thirds were male 
(67%), their median age was 49 years (Inter-quartile range (IQR) 38, 61), with a median time since 
symptom onset of 17 years (IQR 8, 31) (table 1). Of those who had been tested 80% were HLA-B27 
positive. Most participants (67%) met the mNY criteria for AS, an additional 29% fulfilled ASAS imaging 
criteria but not mNY and 4.1% fulfilled only ASAS clinical criteria for axSpA. The median BASDAI and 
ASQoL scores were 4.8 (IQR: 2.5 – 6.8) and 9 (IQR: 3 – 13), respectively. 
 
Factors associated with poor QoL 
Amongst clinical factors, all extra-spinal manifestations, with the exception of uveitis, were associated 
with poorer QoL (table 2). Higher BMI and a greater number of comorbidities were also associated 
with poorer QoL. Longer symptom duration, however, was associated with better QoL (β per year = -
0.05, 95% CI (-0.07, -0.04)). Most patient-reported factors demonstrated a relationship. Worse disease 
activity, function and metrology were significantly associated with poorer QoL (BASDAI (β per unit 
increase = 1.82, BASFI β = 1.56, BASMI β = 0.97). Females reported slightly poorer QoL (β = 1.58, 95% 
CI 1.02, 2.13), and there were important associations with low socio-economic status (e.g. those who 
had attended only secondary school/those living in the highest levels of deprivation had on average 
around 4 points higher ASQoL score than those with a further degree/living in an area with lowest 
levels of deprivation respectively). Current smoking was associated with significantly worse QoL (β = 
4.45 95% CI (3.74, 5.16)). Higher level of fatigue (β per one unit increase in score = 0.63, 95% CI 0.60, 
0.67), fibromyalgia (SSS) (β = 1.34 per unit increase, 95% CI 1.24, 1.44), fibromyalgia (WPI) (β = 0.69, 
95% CI 0.61, 0.77), sleep disturbance (β = 0.56, 95% CI 0.52, 0.59), anxiety (β = 0.72, 95% CI 0.67, 0.76) 
and depression (β =0.97, 95% CI 0.92, 1.01) were all related to poorer QoL. Non-work activity 
impairment due to AS (β = 0.16 per % impairment, 95% CI 0.15, 0.16) was also associated with poor 
QoL. Amongst those working, a higher percentage of time absent (β = 0.11 per % time absent, 95% CI 
0.09, 0.13)), or working with reduced productivity (presenteeism) (β = 0.14 per % time work impaired, 
95% CI 0.13, 0.15)) were related to poor QoL. 
Validation of model predicting poor quality of life 
There were 555 participants in the current study who provided the necessary information to be part 
of the validation of the QoL model reported in the SIRAS study (the lower number was due mainly to 
the fact that WPI was only collected part-way through the study and there were missing data for 
  
BASMI). Four of the previously reported five factors (BASDAI (β = 0.69, 95% CI 0.51, 0.87), BASFI (β = 
0.85, 95% CI 0.69, 1.01), fatigue (β = 0.14, 95% CI 0.08, 0.19) and widespread pain (WPI) (β = 0.07, 95% 
CI 0.00, 0.14)) were related to poor QoL, but there was no independent relationship with BASMI (β = 
0.01, 95% CI -0.16, 0.18) (table 3). A stepwise model was then run with these five factors and additional 
psychosocial factors available in the current study. All three extra added factors (sleep disturbance (β 
= 0.10, 95% CI 0.07, 0.12), anxiety (β = 0.12, 95% CI 0.09, 0.16) and depression (β = 0.19, 95% CI 0.14, 
0.24)) were included in the new best-fitting model, together with disease activity (BASDAI) (β = 0.55, 
95% CI 0.45, 0.64) and function (BASFI) (β = 0.85, 95% CI 0.77, 0.93) (table 4). 
Developing a new model predicting poor QoL 
Finally, a “de novo” stepwise model within BSRBR-AS utilised data from 642 participants. The patient 
reported factors included in the final model were disease activity (BASDAI (β = 0.31, 95% CI 0.14, 0.47), 
function (BASFI (β = 0.59, 95% CI 0.45, 0.73)), depression (β = 0.16, 95% CI 0.09, 0.24) and sleep 
disturbance (β = 0.08 95% CI 0.04, 0.13) in agreement with results of previous models (table 5). In 
addition, activity impairment (β = 0.04, 95% CI 0.02, 0.05), fibromyalgia (SSS) (β = 0.24, 95% CI 0.13, 
0.35) and fibromyalgia (WPI) (β = 0.10, 95% CI, 0.03, 0.17) entered the model as did current tobacco 
smoking (β = 0.66, 95% CI 0.10, 1.21).  
 
DISCUSSION 
 
The results of this study provide consistent evidence of which modifiable factors are associated with 
poor QoL in patients with axSpA. A model previously proposed in a Scotland-wide study was partly 
validated, confirming that worse disease activity, poor function and high levels of fatigue and 
widespread nature of pain symptoms were strongly related to poor QoL. The results were then 
extended by showing that in addition, mood (anxiety, depression), sleep disturbance and both 
widespread pain and somatic symptom components related to fibromyalgia were importantly related 
to poor QoL. 
The participants in BSRBR-AS are broadly representative of the patients with axSpA in clinics across 
Great Britain, with the exception that none of them were currently prescribed biologics (although 
around one third of the participants were about to commence biologics). We have used BASDAI as the 
measure of disease activity as it is the measure most commonly used in the UK and is part of national 
guidelines by the National Institute of Health and Clinical Excellence and the BSR. A second reason is 
that the necessity to have a measure of inflammation (such as for the Ankylosing Spondylitis Disease 
  
Activity Score (ASDAS)) [24] would have resulted in a much higher level of missing data, where this 
had not been measured in the required time-frame.  
Some models have many fewer subjects included than others. This was partly a result of variables 
related to fibromyalgia (WPI and SSS) which were only collected for part of the duration of the study 
and in relation to BASMI which was only measured on some participants. Once the variables included 
in a specific model were determined, the analysis was,however, re-run including all participants with 
the required data available. In validating the model predicting poor QoL, the information collected 
was not in exactly the same format between studies (for pain, WPI was collected instead of CWP). 
However the information collected in BSRBR-AS was more detailed and was analysed in a statistically 
more efficient manner (i.e. using continuous variables where available). Overall the results, however, 
were consistent across both studies. There can be a certain amount of circularity, since factors which 
are potentially associated with poor QoL can themselves be used in assessing QoL. Within ASQoL, for 
example, there are items on function, mental health, sleep and pain. These are all aspects (assessed 
by specific questionnaires) which the current study has found were associated with overall QoL. Such 
circularity is unavoidable but in the current study the regressions model the association per unit 
change in score, so there is limited influence of one aspect of QoL on the overall score and secondly 
in our analysis as part of the SIRAS study, items were removed (in turn) from ASQoL on pain and 
tiredness, and associations with chronic widespread pain and fatigue (respectively) were still 
observed.[7] Finally, one may debate whether function is modifiable independent of disease activity. 
In this dataset, there is a clear correlation between them (correlation = 0.76). We have considered 
both as EULAR recommendations include each as targets for management and the results suggest 
they make an independent contribution to QoL. The correlations between SSS and BASDAI (correlation 
= 0.68) and between BASFI and non-work physical impairment as measured by WPAI (correlation = 
0.78) also suggest important relationships. However, as part of the model assessment we calculated 
the variance inflation factor as a method of assessing potential multicollinearity and this confirmed 
that there were no concerns. 
 
The current study confirms the important role of disease activity and function in terms of QoL but 
adds to the literature by emphasising the important independent role of additional features 
associated with axSpA: mental health, fatigue and sleep problems, and widespread pain. Fatigue has 
been recognised to have an important influence on health-related QoL in rheumatoid arthritis (RA)[25] 
and indeed it was a priority for RA patients who participated in a focus group study in Sweden, in 
terms of being a key component to measure in evaluating treatment success.[26] Zhao et al[27] in a 
meta-analysis of sixteen studies estimated the prevalence of at least moderate depression in patients 
  
with axSpA as 15%, based on a Hospital Anxiety and Depression score of ≥11. Garrido-Cumbrera et al 
[28] in a sample of 680 patients as part of the Atlas of Axial Spondyloarthritis in Spain, reported that 
high disease activity was a risk factor for poor mental health, but the current study emphasises that 
poor mental health independently predicts worse QoL. A meta-analysis of the co-occurrence of 
fibromyalgia in axSpA estimated a prevalence of 13%,[29] compared with a prevalence in the general 
population of around 2-5%[30], and we have previously shown within BSRBR-AS that patients who 
have co-morbid fibromyalgia have the same absolute improvement in QoL when treated with anti-
TNFα therapy, but their QoL prior to and on treatment remains worse. Further, a high score on the 
SSS (rather than the WPI) is predicative of lack of improvement.[31] The fact that these additional 
features are common has been recognised, but not that they contribute independently to poor QoL 
and there has been a lack of studies on how they can be effectively treated (including alongside 
inflammatory arthritis). Nevertheless we acknowledge that there are some who propose that it is 
sufficient to focus on inflammation and that in so doing other aspects which impinge on quality of life 
will also improve [32]. 
 
The most recent EULAR/ASAS guidelines for the management of axial spondyloarthritis state, in 
Recommendation 2, that “the primary goal of treating the patient with axSpA is to maximise long-
term health-related quality of life through control of symptoms and inflammation, prevention of 
progressive structural damage, preservation/normalisation of function and social participation”.[33] 
The results of the current study confirm that disease activity and function as a focus, is appropriate. 
However, it is not sufficient. In the guidelines there is no mention of sleep problems, widespread pain 
or mental health and specifically how these aspects should be managed. The results from this study 
suggest that their role is important – and independent of disease activity and functional limitation. 
Results from others studies, as noted above, suggest that patients will continue to experience fatigue, 
poor mental health and fibromyalgia-like symptoms if management is focused on inflammation 
alone.[3,4] Effecting improvement in such additional disease features is challenging – studies are 
underway to test behavioural approaches to management and/or physical activity for fatigue and 
fibromyalgia symptoms in patients with a range of inflammatory arthritides.[34,35] Currently evidence 
suggests, for example, that community-based exercise programmes exert a positive (albeit modest) 
effect on anxiety[36,37] and depression[38] amongst patients with arthritis and other rheumatic 
conditions. A recent trial demonstrated that group-based cognitive behavioural therapy delivered 
within rheumatology teams reduced the impact of fatigue in RA patients[39].  Such therapy aims to 
reduce the impact of, for example,  fatigue and widespread pain rather then improving symptoms per 
se, and not all patients are willing to engage with them.  Further, the expertise and resources to deliver 
  
the interventions to target these additional factors are not easily available to many rheumatology 
teams.  
In summary, the current study has shown, through analysis of factors related to poor QoL and 
validation of a previously published model, that improving the QoL of patients with axSpA means that 
in addition to improving disease and activity and function in patients, there must be attention to the 
co-morbid features of fatigue, poor sleep and mental health, and other common symptoms. 
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Table 1 Characteristics of the BSRBR-AS patients 
Variable  N % or Median (IQR)* 
Quality of life (ASQoL) Continuous 1810 9(3, 13) 
Clinical factors    
Symptom duration, years Continuous  1809 17.3(7.6, 30.8) 
Uveitis Not present 1364 76.0 
 Present 431 24.0 
Psoriasis Not present 1598 89.0 
 Present 197 11.0 
Inflammatory bowel disease 
(IBD) 
Not present 1617 90.1 
 Present 178 9.9 
Enthesitis Not present 1612 89.8 
 Present 183 10.2 
Peripheral joint disease Not present 1477 82.3 
 Present 318 17.7 
Dactylitis Not present 1726 96.2 
 Present 69 3.8 
Inflammation (CRP), mg/dL Continuous 1404 0.5(0.2, 2.0) 
Body mass index (BMI), kg/m2 Continuous 1810 26.9(23.9, 30.8) 
Number of comorbidities Continuous 1788 0(0, 1) 
Patient reported factors    
Disease activity (BASDAI) Continuous 1785 4.8(2.5, 6.8) 
Physical function (BASFI) Continuous 1801 4.5(2.0, 7.0) 
Spinal mobility (BASMI) Continuous 1340 3.8(2.4, 5.4) 
Age, years Continuous 1810 49.1(37.6, 60.8) 
Gender Male 1208 66.8 
 Female 602 33.2 
Education Secondary school 583 32.5 
 Apprenticeship 173 9.7 
 Further education college 539 30.0 
 University degree 354 19.7 
 Further degree 146 8.1 
Employment Working full-time 870 48.2 
 Working part-time 258 14.3 
 Retired 318 17.6 
 Retired early (ill-health) 103 5.7 
 Unemployed (ill-health), not seeking 
work 
164 9.1 
 Other† 93 5.1 
Deprivation, 1. most deprived 278 15.4 
quintiles of general population    
 2 313 17.3 
 3 382 21.1 
 4 430 23.8 
 5. least deprived 407 22.5 
Smoking status Never 787 44.1 
 Ex 664 37.2 
 Current 334 18.7 
Alcohol consumption Never 122 6.8 
  
*% given for discrete variables, median (IQR) for continuous variables. 
†Because of small numbers in certain categories, we collapsed employment status (Unpaid work, 
Unemployed, but seeking work, Student) into Other. 
 
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis 
Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; CRP, C – reactive protein; 
HADS, Hospital Anxiety and Depression Scale; Jenkins, Jenkins scale for sleep disturbance; WPAI, 
Work Productivity and Activity Impairment. 
 
 Ex 311 17.5 
 Current 1350 75.7 
Chalder fatigue  Continuous 1806 14(11, 19) 
Symptom Severity Scale (SSS) Continuous 675 6(3, 8) 
Widespread pain index (WPI) Continuous 863 4(2, 7) 
Sleep disturbance (Jenkins) Continuous 1796 10(5, 16) 
Anxiety (HADS) Continuous 1788 7(4, 11) 
Depression (HADS) Continuous 1787 5(2, 9) 
Absenteeism (WPAI) (%) Continuous 1011 0(0, 0) 
Presenteeism (WPAI) (%) Continuous 1015 20(10, 50) 
Work impairment (WPAI) (%) Continuous 987 30(10, 50) 
Activity (non-work) impairment 
(%) 
Continuous 1774 40(20, 70) 
  
Table 2 Predictors of ASQoL from univariable linear regression analysis 
Variable  Regression coefficient, 
β, (95% CI)* 
Clinical factors   
Symptom duration (years) Continuous  -0.05(-0.07, -0.04) 
Uveitis Not present - 
 Present -1.32(-1.94, -0.70) 
Psoriasis Not present - 
 Present 1.46(0.62, 2.31) 
Inflammatory bowel disease 
(IBD) 
Not present - 
 Present 1.25(0.36, 2.13) 
Enthesitis Not present - 
 Present 1.72(0.85, 2.60) 
Peripheral joint disease Not present - 
 Present 1.82(1.13, 2.51) 
Dactylitis Not present - 
 Present 0.99(-0.39, 2.37) 
Inflammation (CRP), mg/dL Continuous 0.02(0.00, 0.04) 
Body mass index (BMI), kg/m2 Continuous 0.16(0.10, 0.21) 
Number of comorbidities Continuous 0.75(0.43, 1.07) 
Patient reported factors   
Disease activity (BASDAI) Continuous 1.82(1.75, 1.88) 
Physical function (BASFI) Continuous 1.56(1.51, 1.62) 
Spinal mobility (BASMI) Continuous 0.97(0.82, 1.11) 
Age (years) Continuous -0.05(-0.064, -0.03) 
Gender Male - 
 Female 1.58(1.02, 2.13) 
Education Secondary school - 
 Apprenticeship -1.25(-2.20, -0.30) 
 Further education college -0.97(-1.62, -0.31) 
 University degree -2.78(-3.52, -2.04) 
 Further degree -3.95(-4.96, -2.93) 
Employment Working full-time - 
 Working part-time 1.90(1.89, 2.61) 
 Retired 0.18(-0.48, 0.83) 
 Retired early (ill-health) 5.07(4.02, 6.11) 
 Unemployed (ill-health), not seeking 
work 
8.54(7.69, 9.40) 
 Other† 2.71(1.61, 3.80) 
Deprivation, 1. most deprived - 
quintiles of general population   
 2 -2.20(-3.09, -1.3) 
 3 -3.00(-3.86, -2.14) 
 4 -3.64(-4.48, -2.8) 
 5. least deprived -4.37(-5.22, -3.52) 
Smoking status Never - 
 Ex 1.37(0.80, 1.94) 
 Current 4.45(3.74, 5.16) 
Alcohol consumption Never - 
  
 Ex -0.07(-1.23, 1.09) 
 Current -3.6(-4.63, -2.58) 
Chalder fatigue  Continuous 0.63(0.60, 0.67) 
Symptom Severity Scale (SSS) Continuous 1.34(1.24, 1.44) 
Widespread pain index (WPI) Continuous 0.69(0.61, 0.77) 
Sleep disturbance (Jenkins) Continuous 0.56(0.52, 0.59) 
Anxiety (HADS) Continuous 0.72(0.67, 0.76) 
Depression (HADS) Continuous 0.97(0.92, 1.01) 
Absenteeism (WPAI) (%) Continuous 0.11(0.09, 0.13) 
Presenteeism (WPAI) (%) Continuous 0.14(0.13, 0.15) 
Work impairment (WPAI) (%) Continuous 0.14(0.13, 0.15) 
Activity (non-work) impairment 
(%) 
Continuous 0.16(0.15, 0.16) 
*A positive regression coefficient means a poorer quality of life compared with a reference category 
or per unit increase in the risk factor, for continuous variables. 
†Because of small numbers in certain categories, we collapsed employment status (Unpaid work, 
Unemployed, but seeking work, Student) into Other. 
 
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis 
Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; CRP, C – reactive protein; 
HADS, Hospital Anxiety and Depression Scale; Jenkins, Jenkins scale for sleep disturbance; WPAI, 
Work Productivity and Activity Impairment. 
  
Table 3 Validation of a model predicting poor quality of life 
Variable 
 
Model derived from SIRAS study* BSRBR-AS model** 
  Relative Risk 
(95% CI) 
Regression coefficient, 
β, (95% CI)† 
Disease activity (BASDAI) BASDAI < 4 1.00 0.69(0.51, 0.87) 
 BASDAI ≥ 4 1.52(1.09, 2.12)  
Physical function (BASFI) BASFI < 4 1.00 0.85(0.69, 1.01) 
 BASFI ≥ 4 3.46(1.76, 6.82)  
Spinal mobility (BASMI) BASMI < 4 1.00 0.01(-0.16, 0.18) 
 BASMI ≥ 4 1.52(0.93, 2.50)  
Fatigue None/mild 1.00 0.14(0.08, 0.19) 
 Moderate/severe 1.60(1.13, 2.28)  
Widespread pain index 
(WPI)‡ 
No 1.00 0.07(0.00, 0.14) 
 Yes 1.92(1.33, 2.75)  
N=555 
*Scotland Registry of Ankylosing Spondylitis. 
**Model adjusted for gender, age, education, symptom duration, employment, deprivation, alcohol 
consumption, and history of peripheral joint involvement. 
†All variables in the model are continuous (in contrast to dichotomous in SIRAS). 
‡Chronic Widespread Pain was available in SIRAS and WPI was available in BSRBR-AS. 
 
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis 
Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; SIRAS, Scotland Registry for 
Ankylosing Spondylitis; BSRBR-AS, British Society for Rheumatology Biologics Register in Ankylosing 
Spondylitis. 
  
  
 
Table 4 Validation of a model predicting poor QoL – the additional role of depression, anxiety and 
sleep disturbance 
Variable Regression coefficient, β, (95% CI)*† 
Disease activity (BASDAI) 0.55(0.45, 0.64) 
Physical function (BASFI) 0.85(0.77, 0.93) 
Sleep disturbance (Jenkins) 0.10(0.07, 0.12) 
Anxiety (HADS) 0.12(0.09, 0.16) 
Depression (HADS) 0.19(0.14, 0.24) 
N=1692 
*Model adjusted for gender, age, education, symptom duration, employment, deprivation, alcohol 
consumption,  history of peripheral joint involvement and number of comorbidities. 
†Regression coefficients represents change in QoL per unit increase in predictor. 
 
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis 
Functional Index; HADS, Hospital Anxiety and Depression Scale; Jenkins: Jenkins scale for sleep 
disturbance. 
  
Table 5 Variables associated with poor quality of life: the BSRBR-AS study 
Variable*  Regression coefficient, β, (95% CI)† 
Disease activity (BASDAI) per unit increase 0.31(0.14, 0.47) 
Physical function (BASFI) per unit increase 0.59(0.45, 0.73) 
Symptom Severity Scale (SSS) per unit increase 0.24(0.13, 0.35) 
Widespread pain index (WPI) per unit increase 0.10(0.03, 0.17) 
Sleep disturbance (Jenkins) per unit increase 0.08(0.04, 0.13) 
Depression (HADS) per unit increase 0.16(0.09, 0.24) 
Activity (non-work) impairment (%) per % increase 0.04(0.02, 0.05) 
Smoking – current smoker Yes/No 0.66(0.10, 1.21) 
N=642 
*Work variables were not offered to the model as these were only relevant to persons in 
employment. Inflammation not offered to the model because of level of missing data. 
†Model adjusted for gender, age, education, symptom duration, current employment, deprivation, , 
history of peripheral joint involvement, uveitis, psoriasis, inflammation bowel disease, enthesitis, 
dactylitis and number of comorbidities. 
 
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis 
Functional Index; HADS, Hospital Anxiety and Depression Scale; Jenkins, Jenkins scale for sleep 
disturbance. 
 
 
